HIV trial stopped early after good resultsBMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7082.695l (Published 08 March 1997) Cite this as: BMJ 1997;314:695
- Alison Boulton
A United States National Institutes of Health trial of patients with advanced HIV disease has been stopped early because a combination of three drugs showed significant benefits.
The US National Institute of Allergy and Infectious Diseases study known as ACTG 320 examined the safety and efficacy of adding a protease inhibitor (indinavir) to two nucleoside analogue reverse transcriptase inhibitors-zidovudine and lamivudine. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial